GeorgeJHannaMD(He/Him)

Infectious Disease • Princeton, NJ

HIV/AIDS Medicine

Independent Biopharmaceutical Consultant with Expertise in Clinical Drug Development, Scientific and Medical Affairs, and Infectious Diseases

Join to view full profile

Dr. Hanna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hanna's full profile

Already have an account?

Office
1805 Stuart Rd W
Princeton, NJ 08540

Education & Training

Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 1996 - 2000
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1995
Baylor College of MedicineClass of 1992

Certifications & Licensure

NJ State Medical License 2009 - 2025
PA State Medical License 2001 - 2024
IL State Medical License 2005 - 2008
MA State Medical License 1995 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects Start of enrollment: 1997 Nov 01
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

124 citations
Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting
Boris Julg, Lynda Dee, Jintanat Ananworanich, Dan H. Barouch, Katharine J. Bar
The Lancet. HIV. 2019-04-01
39 citations
Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Matthew W McCarthy, Susanna Naggie, David R Boulware, Christopher J Lindsell, Thomas G Stewart
JAMA. 2023-01-24
16 citations
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results F...
Pedro Cahn, Paul E. Sax, Kathleen Squires, Jean-Michel Molina, Winai Ratanasuwan
Journal of Acquired Immune Deficiency Syndromes. 2018-08-15

Journal Articles

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immun...
George J Hanna, Peter Sklar, Kathleen E Squires, Paul E Sax, Carey Hwang, Clinical Infectious Diseases

Press Mentions

Merck’s Pifeltro (Doravirine) and Delstrigo (doravirine/lamivudine/tenofovir Disoproxil Fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically SuppressedSeptember 24th, 2019
FDA Approves Expanded Indications for 2 HIV TherapiesSeptember 20th, 2019
Merck Announces Presentation of Phase 2b Results for Investigational HIV-1 Therapy Islatravir (MK-8591) at IAS 2019July 24th, 2019
Join now to see all

Grant Support

Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases2001
Selection Of Multidrug Resistant Hiv-1rtNational Institute Of Allergy And Infectious Diseases1999–2001

Professional Memberships

American College of Physicians - ACP
Member
Infectious Disease Society of America - IDSA
Member

External Links

LinkedInhttps://www.linkedin.com/in/george-hanna-35221924/